By: Tara Roberts – University of Miami –
Research led by Joshua Hare, M.D., helped lay the foundation for laromestrocel, an investigational cell therapy that Longeveron will test for its effects on aging frailty, muscle function, cognition and immune function.
When older adults become physically frail, they run a higher risk of falls, hospitalization and death. People with aging frailty may have exhaustion, weakness, slow walking speed and other symptoms, according to the American Academy of Physical Medicine and Rehabilitation.
Joshua Hare, M.D., director of the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine, studies how mesenchymal stem cell therapy can treat aging frailty and other important medical conditions. In 2014, he served as scientific co-founder of a Miami-based biotech company, Longeveron, which licensed that stem cell technology from UM. In August 2026, after 12 years of research, Longeveron was named a finalist for the global XPRIZE Healthspan competition.


